Kathleen Pepski Appointed to Intricon BOD

Kathleen Pepski

Kathleen Pepski appointment becomes effective March 19, 2021.

“We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long-term growth strategy.”

Kathleen Pepski career includes more than 30 years of finance and accounting experience at several manufacturing and distribution companies. Most recently she served as the Vice President, CFO and Treasurer at Hawkins, Inc.

Kathleen Pepski career includes executive and VP level positions with companies such as PNA Holdings, Hoffman Enclosures, BMC Industries, Inc., and The Valspar Corporation. She has more than 25 years of experience working with boards of publicly held companies as the top finance or accounting executive. She is currently serving on the board of Lakewood Cemetery Association and previously served on the boards of Delta Dental Benefit Plans of MN and The Bergquist Company. Ms. Pepski’s experience also includes executing several M&A deals as well as being a lead advisor for strategic planning, annual operating plans, and capital allocation matters.

“It is a pleasure to welcome Kathleen Pepski to our board of directors,” said Philip I. Smith, Intricon’s Chairman of the Board. “I am confident that with her background and wide-ranging business experiences, Ms. Pepski will provide a valuable perspective to execute our long-term strategy and build value for the Intricon shareholder base.”

“I am very excited to join Intricon, a company with a strong foundation and significant growth opportunities ahead,” said Ms. Pepski. “My background aligns very well with the Intricon mission and I am looking forward to advising on future innovation at the forefront of the miniature medical device market.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”